Spider Venom-Derived Drug IB409 Enters Phase 1 Clinical Trial for Heart Attack and Stroke Treatment
Key Insights
Australian researchers have launched a Phase 1 clinical trial for IB409 (search), a novel drug derived from funnel-web spider venom that could prevent cell death during heart attacks and strokes.
The drug is based on Hi1a (search), a protein from Fraser Island funnel-web spider venom that showed "exceptionally promising" preclinical results in protecting heart tissue from oxygen deprivation damage.
Infensa Bioscience (search) has transformed Hi1a (search) into IB409 (search), a miniaturized peptide suitable for drug development, addressing an unmet medical need as no existing drugs prevent damage caused by heart attacks and strokes.
A groundbreaking Phase 1 clinical trial has commenced in Australia for IB409 (search), a potentially life-saving treatment for heart attacks and strokes derived from the venom of one of the world's deadliest spiders. The novel drug, developed by biotechnology company Infensa Bioscience (search) in collaboration with the University of Queensland (UQ), represents the first therapeutic approach designed to prevent cellular damage during cardiovascular events.
Novel Mechanism Targets Oxygen Deprivation Damage
The current Phase 1 clinical study will assess the safety, tolerability and dosage of IB409 (search), which was developed from a molecule found in Australian funnel-web spider venom. Professor Glenn King from UQ's Institute for Molecular Bioscience explained that the drug is based on Hi1a (search), a protein derived from the venom of a funnel-web spider found on Queensland's Fraser Island.
"We believe that Hi1a (search) could reduce damage to the heart and brain during heart attacks and strokes by preventing cell death caused by lack of oxygen," King said. His team has published "exceptionally promising" preclinical results demonstrating that Hi1a effectively protects the heart, with subsequent studies subjecting it to preclinical tests that mimic real-life treatment scenarios.
From Venom to Viable Drug Candidate
The Infensa team has successfully transformed the naturally occurring Hi1a (search) protein into IB409 (search), a miniaturized peptide suitable for pharmaceutical development. This engineering achievement represents a critical step in translating the spider venom compound into a clinically viable therapeutic option.
Professor Mark Smythe, CEO of Infensa Bioscience (search) and UQ researcher, emphasized the significant unmet medical need that IB409 (search) could address. "If the Phase 1 and subsequent clinical trials of IB409 show that it can safely and effectively treat heart attacks, we could improve the lives of millions of people living with heart disease around the world," Smythe stated.
Addressing Critical Treatment Gap
The development of IB409 (search) addresses a fundamental limitation in current cardiovascular care. As Smythe noted, no existing drugs prevent the damage caused by heart attack and stroke, highlighting the potential significance of this spider venom-derived therapeutic approach.
The Phase 1 trial marks a pivotal moment in the translation of this unique natural compound from laboratory discovery to potential clinical application, offering hope for a new class of cardioprotective therapies that could transform treatment outcomes for cardiovascular patients worldwide.